|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1272855372 |
| 003 |
OCoLC |
| 005 |
20231120010607.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
211001s2021 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d EBLCP
|d OCLCF
|d SFB
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1269618081
|a 1272954534
|
| 020 |
|
|
|a 9780323851237
|q (electronic bk.)
|
| 020 |
|
|
|a 0323851231
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323851220
|
| 020 |
|
|
|z 0323851223
|
| 035 |
|
|
|a (OCoLC)1272855372
|z (OCoLC)1269618081
|z (OCoLC)1272954534
|
| 050 |
|
4 |
|a RC382
|
| 082 |
0 |
4 |
|a 616.833
|2 23
|
| 245 |
0 |
0 |
|a Autonomic dysfunction in Parkinson's disease /
|c edited by Cristian Falup-Pecurariu.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2021.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a International review of movement disorders ;
|v v. 1
|
| 505 |
0 |
|
|a Intro -- Autonomic Dysfunction in Parkinson�s Disease -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Autonomic nervous system-Anatomy, physiology, biochemistry -- 1. Anatomy of the autonomic nervous system (ANS) -- 1.1. Central autonomic network -- 1.2. Peripheral autonomic nervous system -- 1.3. Sympathetic system -- 1.4. Parasympathetic system -- 2. Physiology and biochemistry of the autonomic nervous system -- 2.1. Sympathetic system -- 2.2. Parasympathetic system -- 2.3. The fundamentals of ANS function -- 2.4. The sympathetic and parasympathetic interaction -- 3. Autonomic control of selected organ systems -- 3.1. Cardiovascular autonomic control -- 3.2. Autonomic control of bladder -- 3.3. Gastrointestinal autonomic control -- 3.4. Clinical implications and conclusion -- References -- Chapter Two: General approach to patients with autonomic dysfunction in Parkinson�s disease -- 1. Introduction -- 2. Epidemiology -- 3. Pathophysiology -- 3.1. Primary autonomic dysfunction in Parkinson�s disease -- 3.2. Secondary autonomic dysfunction in Parkinson�s disease -- 4. Clinical expression -- 5. Diagnosis -- 5.1. Validated scales and questionnaires -- 5.2. Function tests -- 6. Treatment -- 7. Prognosis -- 8. Conclusion -- Acknowledgments -- References -- Chapter Three: Rating scales for dysautonomia in Parkinson�s disease -- 1. Introduction -- 2. Method -- 3. Scales -- 4. General assessment scales -- 4.1. Non-motor symptoms questionnaire -- 4.1.1. Scale description -- 4.1.2. Properties of the NMS-quest -- 4.1.2.1. Sensitivity and specificity -- 4.1.2.2. Construct validity -- 4.1.2.3. Reliability -- 4.1.2.4. Acceptability -- 4.1.2.5. Strengths and weaknesses -- 4.1.2.6. Conclusions -- 4.2. The non-motor symptoms scale (NMSS) -- 4.2.1. Scale description -- 4.2.2. Properties of the questionnaire -- 4.2.2.1. Validity.
|
| 505 |
8 |
|
|a 4.2.2.2. Reliability -- 4.2.2.3. Acceptability -- 4.2.2.4. Strengths and weaknesses -- 4.2.3. Conclusions -- 4.3. COMPASS -- 4.3.1. Scale description -- 4.3.2. Properties of the questionnaire -- 4.3.2.1. Content validity -- 4.3.2.2. Construct validity -- 4.3.2.3. Strengths and weaknesses -- 4.3.2.4. Conclusion -- 4.4. COMPASS-31 -- 4.4.1. Scale description -- 4.4.2. Properties of the questionnaire -- 4.4.2.1. Content validity -- 4.4.2.2. Construct validity -- 4.4.2.3. Internal consistency -- 4.4.2.4. Strengths and weaknesses -- 4.4.2.5. Conclusion -- 4.5. MDS-unified Parkinson�s disease rating scale (MDS-UPDRS) -- 4.5.1. Scale description -- 4.5.1.1. Strengths and weaknesses -- 4.5.1.2. Conclusion -- 4.6. The scale for outcomes in Parkinson�s disease-autonomic (SCOPA-AUT) -- 4.6.1. Scale description -- 4.6.2. Properties of the questionnaire -- 4.6.2.1. Content validity -- 4.6.2.2. Construct validity -- 4.6.2.3. Reliability -- 4.6.2.4. Acceptability -- 4.6.2.5. Strengths and weaknesses -- 4.6.2.6. Conclusion -- 5. Dysautonomia rating scales -- 5.1. Gastrointestinal dysfunction -- 5.2. MDS-UPDRS -- 5.3. COMPASS and COMPASS 31 -- 5.4. The non-motor symptoms questionnaire (NMS quest) -- 5.4.1. Strengths and weaknesses -- 5.5. The non-motor symptoms scale (NMSS) -- 5.5.1. Strengths and weaknesses -- 5.6. SCOPA-AUT -- 5.6.1. Strengths and weaknesses -- 5.6.2. Conclusion -- 6. Symptom specific scales -- 6.1. Dysphagia -- 6.2. Swallowing disturbance questionnaire (SDQ) -- 6.2.1. Clinimetric properties -- 6.2.2. Strengths -- 6.2.3. Conclusions -- 6.3. Dysphagia-specific quality of life (SWAL-QOL) -- 6.3.1. Clinimetric properties -- 6.3.1.1. Internal consistency -- 6.3.1.2. Construct validity -- 6.3.2. Acceptability -- 6.3.3. Strengths -- 6.3.4. Conclusions -- 6.4. The Munich dysphagia test for Parkinson�s disease (MDT-PD) -- 6.4.1. Clinimetric properties.
|
| 505 |
8 |
|
|a 6.4.1.1. Internal consistency -- 6.4.1.2. Diagnostic validity and cross-validity -- 6.4.1.3. Construct validity -- 6.4.1.4. Strengths -- 6.4.1.5. Limits -- 6.4.1.6. Conclusions -- 6.5. The Radbout oral motor inventory for Parkinson�s disease (ROMP) -- 6.5.1. Clinimetric properties -- 6.5.1.1. Reliability and reproductibility -- 6.5.1.2. Acceptability -- 6.5.1.3. Construct validity -- 6.5.1.4. Conclusion -- 6.5.2. Sialorrhea -- 6.6. Sialorrhea clinical scale for PD (SCS-PD) -- 6.6.1. Clinimetric properties -- 6.6.1.1. Reliability -- 6.6.1.2. Construct validity -- 6.6.1.3. Acceptability -- 6.6.1.4. Sensitivity and specificity -- 6.6.1.5. Strengths -- 6.6.1.6. Limits -- 6.6.1.7. Conclusion -- 6.7. Drooling rating scale (DRS) -- 6.7.1. Clinimetric properties -- 6.7.1.1. Strengths -- 6.7.1.2. Limits -- 6.7.1.3. Conclusion -- 6.8. Drooling severity and frequency scale (DSFS) -- 6.8.1. Clinimetric properties -- 6.8.1.1. Strengths -- 6.8.1.2. Limits -- 6.8.1.3. Conclusion -- 6.9. The Radbout oral motor inventory for Parkinson�s disease (ROMP) -- 6.9.1. Clinimetric properties -- 6.9.1.1. Reliability and reproductibility -- 6.9.1.2. Acceptability -- 6.9.1.3. Construct validity -- 6.9.1.4. Conclusions -- 6.9.2. Constipation -- 6.9.3. ROME criteria -- 6.9.4. Strengths -- 6.9.5. Limits -- 6.10. Other assessment tools -- 6.11. Urinary dysfunction -- 6.11.1. Introduction, definition and assessment of urinary dysfunction -- 6.11.2. Scales and questionnaires -- 6.12. SCOPA AUT -- 6.13. NMS-QUEST -- 6.14. NMS-SCALE -- 6.15. COMPASS. COMPASS 31 -- 6.16. MDS-UPDRS -- 6.17. International consultation on incontinence questionnaire (ICIQ) -- 6.18. Clinimetric properties -- 6.18.1. Content validity -- 6.18.2. Construct validity -- 6.18.3. Convergent validity -- 6.18.4. Internal consistency -- 6.18.5. Sensitivity -- 6.18.6. Conclusion.
|
| 505 |
8 |
|
|a 6.19. International consultation on incontinence questionnaire-male LUTS (ICIQ-MLUTS) -- 6.19.1. Description -- 6.19.2. Clinimetric properties -- 6.19.2.1. Internal consistency -- 6.19.2.2. Test-retest reliability -- 6.19.2.3. Criterion validity -- 6.19.2.4. Conclusion -- 6.20. Overactive bladder questionnaire (OABq)/OABq short form/eight-item OABq score/OAB symptom score -- 6.20.1. Description -- 6.20.2. Clinimetric properties -- 6.20.2.1. Test-retest reliability -- 6.20.2.2. Internal consistency -- 6.20.2.3. Convergent validity -- 6.20.2.4. Conclusion -- 6.21. Danish prostatic symptom score -- 6.21.1. Clinimetric properties -- 6.21.1.1. Test-retest reliability -- 6.21.1.2. Internal consistency -- 6.21.1.3. Conclusion -- 6.22. International prostate symptom score -- 6.22.1. Clinimetric properties -- 6.22.1.1. Internal consistency -- 6.22.1.2. Test-retest reliability -- 6.22.1.3. Sensitivity to change/responsiveness -- 6.22.1.4. Conclusions -- 6.23. The questionnaire on pelvic organ function -- 6.23.1. Clinimetric properties -- 7. Sexual dysfunction -- 7.1. Introduction, definition and assessment of sexual dysfunction -- 7.2. Scales and questionnaires -- 7.3. Scales/questionnaires designed to assess non-motor symptoms -- 7.4. SCOPA AUT -- 7.4.1. Clinimetric properties -- 7.5. NMS-QUEST -- 7.5.1. Clinimetric properties -- 7.6. NMS SCALE -- 7.6.1. Clinimetric properties -- 7.7. COMPASS 31 -- 7.8. MDS-UPDRS -- 7.9. Scales focused on the sexual dysfunctions -- 7.10. The Arizona sexual experience scale -- 7.11. Clinimetric properties -- 7.12. Quality of sexual life questionnaire -- 7.12.1. Clinimetric properties -- 7.13. Orthostatic hypotension -- 7.13.1. Introduction, definition and assessment orthostatic hypotension -- 7.13.2. Scales and questionnaires -- 7.14. SCOPA-AUT -- 7.14.1. Strengths and weaknesses -- 7.14.2. Conclusion -- 7.15. COMPASS.
|
| 505 |
8 |
|
|a 7.15.1. Strengths and weaknesses -- 7.15.1.1. Conclusion -- 7.16. COMPASS-31 -- 7.16.1. Strengths and weaknesses -- 7.16.2. Conclusion -- 7.17. The non-motor symptoms questionnaire (NMS quest) -- 7.17.1. Strengths and weaknesses -- 7.17.2. Conclusion -- 7.18. The non-motor symptoms scale (NMSS) -- 7.18.1. Strengths and weaknesses -- 7.18.2. Conclusion -- 7.19. MDS-UPDRS Part I -- 7.19.1. Strengths and weaknesses -- 7.19.2. Conclusion -- 7.20. Orthostatic grading scale (OGS) -- 7.20.1. Scale description -- 7.20.2. Properties of the scale -- 7.20.2.1. Content validity -- 7.20.2.2. Internal consistency -- 7.20.2.3. Construct validity -- 7.20.2.4. Strengths and weaknesses -- 7.20.2.5. Conclusion -- 7.20.3. Conclusions -- References -- Chapter Four: Assessing autonomic dysfunction with functional imaging in Parkinson�s disease -- 1. Introduction -- 2. Imaging synaptic dysfunction and denervation of the autonomic nervous system -- 2.1. Sympathetic denervation -- 2.2. Parasympathetic denervation -- 2.3. Brain-first versus body-first PD -- 3. Imaging functional disturbances of the autonomic nervous system -- 3.1. Gastrointestinal tract -- 3.1.1. Oropharynx and esophagus -- 3.1.2. Stomach -- 3.1.3. Small intestine -- 3.1.4. Colon -- 3.1.5. Anorectal -- 3.2. Urinary tract -- 3.3. Thermoregulation of the skin -- 4. Conclusion -- References -- Chapter Five: Cardiovascular autonomic failure in Parkinson�s disease -- 1. Introduction -- 2. Clinical presentation of cardiovascular autonomic failure in PD -- 2.1. Orthostatic hypotension -- 2.2. Post-prandial hypotension -- 2.3. Exercise-induced hypotension -- 2.4. Supine and nocturnal hypertension -- 3. Diagnostic work-up of cardiovascular autonomic failure -- 3.1. Diagnosis of neurogenic OH -- 3.2. Diagnosis of supine and nocturnal hypertension.
|
| 650 |
|
0 |
|a Parkinson's disease.
|
| 650 |
|
0 |
|a Dysautonomia.
|
| 650 |
|
2 |
|a Autonomic Nervous System Diseases
|0 (DNLM)D001342
|
| 650 |
|
6 |
|a Maladie de Parkinson.
|0 (CaQQLa)201-0016037
|
| 650 |
|
6 |
|a Dysautonomie.
|0 (CaQQLa)201-0356215
|
| 650 |
|
7 |
|a Dysautonomia
|2 fast
|0 (OCoLC)fst00900337
|
| 650 |
|
7 |
|a Parkinson's disease
|2 fast
|0 (OCoLC)fst01053693
|
| 700 |
1 |
|
|a Falup-Pecurariu, Cristian.
|
| 776 |
0 |
8 |
|i Ebook version :
|z 9780323851237
|
| 776 |
0 |
8 |
|i Print version:
|t Autonomic dysfunction in Parkinson's disease.
|d Cambridge, MA : Academic Press, 2021
|z 0323851223
|z 9780323851220
|w (OCoLC)1240305944
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/26667878/1
|z Texto completo
|
